Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.47 |
| ▸ | CA1 | P00915 | 8/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.36 |
| ▸ | CA6 | P23280 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486014 | 0.84 | CA2 (0.51) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL858994 | 0.82 | CA1 (0.53) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL2421543 | 0.73 | LMNA (0.44) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL29469809 | 0.72 | CA1 (0.58) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL2227362 | 0.72 | CA1 (0.58) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL2421539 | 0.72 | LMNA (0.43) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL1281418 | 0.72 | CA2 (0.46) | CA2CA1CA9MEN1KMT2A | |
| SCHEMBL578867 | 0.71 | CA2 (0.45) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL3717326 | 0.71 | CA2 (0.45) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL3717781 | 0.71 | CA2 (0.45) | CA2CA1CA9MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198907-B2 | Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent | PTC THERAPEUTICS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-8841302-B2 | HCV inhibitor and therapeutic agent combinations | PTC THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120087893-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PTC THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2417122-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | CA2 3704/4885CA1 4155/4885CA9 3940/4885 |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | CA2 3559/4885CA1 4515/4885CA9 4223/4885 |
| US-20120087893-A1 | COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT | PREP, ENPEP, DNPEP | CA2 3259/4885CA1 3381/4885CA9 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.